Ascentage Pharma Stock Could More Than Double: Analyst

William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Outperform rating.

Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46

Citigroup analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Buy rating and announces Price Target of $46.

Citizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35

Citizens analyst Silvan Turkcan initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Market Outperform rating and announces Price Target of $35.

Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s

Takeda Reports TAK-881 Cuts Infusion Volume 50%, Single-Site Infusion Time 42.6% Vs. HyQvia In Phase 2/3 Immunodeficiency Trial

Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis

Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance